Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASH 2024 Updates on Bispecific Therapies in B-Cell Lymphomas
Panelists discuss how exciting new data from ASH 2024 on bispecific therapies for B-cell lymphomas, including epcoritamab in diffuse large B-cell lymphoma, mosunetuzumab in follicular lymphoma, and odronextamab are shaping treatment algorithms by providing long-term follow-up data that could influence therapeutic strategies and patient management.
Video content above is prompted by the following:
- There is a wealth of exciting data emerging from ASH 2024 on bispecific therapies for B-cell lymphomas. Before we discuss these new findings, which bispecific therapies were already available for B-cell lymphomas? How were they typically positioned within treatment algorithms?
- Let’s discuss some of the long-term data updates being presented. How do the 3-year follow-up data on epcoritamab in DLBCL impact its role in your treatment algorithms?
- 4-year follow-up data for mosunetuzumab in follicular lymphoma were also presented. What are the key insights from these data?
Related Videos
